These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 3493845)

  • 1. Studies on the recovery from tolerance to tumor antigens. II. Accelerated recovery of tumor-specific effector T cells in tolerant mice by applying T-T cell interaction mechanism.
    Sato S; Fujiwara H; Kosugi A; Hamaoka T
    Cancer Immunol Immunother; 1987; 24(2):121-6. PubMed ID: 3493845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the recovery from tolerance to tumor antigens. I. Bone marrow cells from tolerant hosts are not rendered tolerant, but provide potential to reconstitute tumor-specific effector T cell clones.
    Fujiwara H; Sato S; Kosugi A; Fukuzawa M; Hamaoka T
    Cancer Immunol Immunother; 1987; 24(2):113-20. PubMed ID: 3493844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity.
    Sano H; Kosugi A; Sano S; Fujiwara H; Hamaoka T
    Cancer Immunol Immunother; 1987; 25(3):180-4. PubMed ID: 2960447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The generation of tumor-specific in vivo protective immunity in the tumor mass from mice rendered tolerant to tumor antigens.
    Sano S; Izumi Y; Sugihara S; Nakajima H; Fujiwara H; Hamaoka T
    Cancer Immunol Immunother; 1987; 25(2):105-10. PubMed ID: 3499223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-reactivity between haptenic muramyl di- or tripeptide derivatives and Mycobacterium bovis BCG: potential application for enhancing tumor immunity.
    Kosugi A; Shima J; Sano H; Ogata M; Kusama T; Fujiwara H; Hamaoka T
    Infect Immun; 1986 Dec; 54(3):768-73. PubMed ID: 3491048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. I. Synthesis of a novel haptenic MDP derivative cross-reactive with Bacillus Calmette Guerin and its application to enhanced induction of tumor immunity.
    Hamaoka T; Takai Y; Kosugi A; Mizushima Y; Shima J; Kusama T; Fujiwara H
    Cancer Immunol Immunother; 1985; 20(3):183-8. PubMed ID: 2933141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of helper T cells on prevention of tolerance induction in effector T cells responsible for syngeneic tumor immunity.
    Fujiwara H; Kinouchi T; Tsuchida T; Aoki H; Hamaoka T
    Gan; 1982 Oct; 73(5):766-72. PubMed ID: 6219908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity.
    Shima J; Yoshioka T; Nakajima H; Fujiwara H; Hamaoka T
    Cancer Immunol Immunother; 1988; 26(1):43-7. PubMed ID: 2964268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
    Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T
    J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mechanism of specific suppression in effector T cell clones against tumor-associated transplantation antigens.
    Fujiwara H; Tsuchida T; Mizuochi T; Kohmo T; Hamaoka T
    Gan; 1981 Oct; 72(5):732-41. PubMed ID: 7035282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerance induction in tumor-specific effector T cells by presensitization with tumor antigens via the intragastric route.
    Hashimoto T; Okuno K; Tsuchida T; Fujiwara H; Hamaoka T
    Gan; 1984 Jul; 75(7):610-6. PubMed ID: 6236126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo.
    Yoshioka T; Fukuzawa M; Takai Y; Wakamiya N; Ueda S; Kato S; Fujiwara H; Hamaoka T
    Cancer Immunol Immunother; 1986; 21(3):193-8. PubMed ID: 2938736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmented induction of tumor-specific resistance by priming with Mycobacterium tuberculosis (TBC) and subsequent immunization with PPD-coupled syngeneic tumor cells.
    Takatsu K; Hamaoka T; Tominaga A; Kanamasa Y
    J Immunol; 1980 Dec; 125(6):2367-73. PubMed ID: 6776192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppressive effect of portal venous inoculation with tumor cells on the anti-tumor immune potential.
    Kokudo S; Qian JH; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1987 Sep; 78(9):946-51. PubMed ID: 3117751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation of antitumor immune response by trinitrophenyl (TNP)-reactive helper T-cells: enhanced induction of tumor-specific Lyt-1+2- T-cell-mediated delayed-type hypersensitivity from spleen cells of tumor-bearing mice by TNP helpers.
    Suda T; Fujiwara H; Mizushima Y; Shearer GM; Hamaoka T
    J Natl Cancer Inst; 1986 Dec; 77(6):1267-72. PubMed ID: 2948049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The activation of L3T4+ helper T cells assisting the generation of anti-tumor Lyt-2+ cytotoxic T lymphocytes: requirement of Ia-positive antigen-presenting cells for processing and presentation of tumor antigens.
    Kosugi A; Yoshioka T; Suda T; Sano H; Takahama Y; Fujiwara H; Hamaoka T
    J Leukoc Biol; 1987 Dec; 42(6):632-41. PubMed ID: 2960766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
    Fujiwara H; Yoshioka T; Shima J; Kosugi A; Itoh K; Hamaoka T
    J Immunol; 1986 Apr; 136(7):2715-9. PubMed ID: 3005417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-T cell interaction in the induction of delayed-type hypersensitivity (DTH) responses: vaccinia virus-reactive helper T cell activity involved in enhanced in vivo induction of DTH responses and its application to augmentation of tumor-specific DTH responses.
    Takai Y; Kosugi A; Yoshioka T; Tomita S; Fujiwara H; Hamaoka T
    J Immunol; 1985 Jan; 134(1):108-13. PubMed ID: 3155458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additional evidence for the augmented induction of tumor-specific resistance in vaccinia virus-primed mice by immunization with vaccinia virus-modulated syngeneic tumor cells.
    Ueda S; Wakamiya N; Wu KS; Kato S; Fujiwara H; Hamaoka T
    Biken J; 1984 Mar; 27(1):1-7. PubMed ID: 6385960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The augmentation of tumor-specific immunity by virus help. II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus-reactive helper T cells.
    Shimizu Y; Fujiwara H; Ueda S; Wakamiya N; Kato S; Hamaoka T
    Eur J Immunol; 1984 Sep; 14(9):839-43. PubMed ID: 6236991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.